| 释义 |
biosimilarsEconomist²⁶⁷⁷⁸⁺⁵
基本例句
🌏生物仿制药；生物相似药；生技仿制药
And he supports efforts to encourage“ biosimilars”, a form of generic rival to biotech drugs, which the industry hates.
同时，不顾制药业的反对，麦凯恩还鼓励研制生物仿制药—— 这种基因药物是生化药物的竞争对手。 ecocn
It will spend about half of the2.1 trillion won budget on developing biosimilars and use the other half to build factories, he said.
他说，三星集团将花费2100万韩元投资中的一般用于开发生物仿制药，而另一半用于建设生产厂。 blog.sina.com.cn
The science involved in making biosimilars is much more complicated than that in making ordinary generics, says Andrew Pasternak of Bain & Company, a consultancy.
贝恩咨询公司的安德鲁帕斯特纳克说，制造生物仿制药品的科学要比制造普通的非专利药品更加复杂。 ecocn
And because biosimilars are not exact copies, many countries may not allow them to be automatically substituted for the pricier originals, as generic drugs often are in some countries.
而且由于仿生物药品并非是原样复制，因此与非专利药品在众多国家流行不同，许多国家或许不允许用仿生物药品自动替换价格高昂的原始生物药品。 ecocn
As industry increases its focus on biosimilars, has the complexity or scope of your projects changed?
作为行业增加其对生物仿制药的关注，有您的项目的复杂程度或范围改变？ pharmst
First, they are much harder to copy, so generic equivalents called“ biosimilars” will be slow in coming.
首先,该行业技术更难效仿,通用一个药名的制剂生物仿制药很难出现. ecocn
He points to his firm’s aggressive entry into the nascent market for “ biosimilars”, which are the generic equivalents of biotechnology drugs, as proof that firms like his need not be toothless.
他指出，山德士积极进入“生物仿制药【译注12】”即生物技术药的对等仿制物新兴市场，这证明象他们这样的公司并非人微言轻。 ecocn
In biotech drugs the company plans to begin as a contract manufacturer of biosimilarsgeneric versions of biotech drugs and has partnered with Quintiles, a drug outsourcer.
最后，在生物制药上，三星计划以生物仿制药物生物制药都含有的一般物质的合约生产商开始做起，并与制药外包商昆泰联合。 ecocn
Sales of biosimilars at Sandoz, a generics arm of Novartis, a Swiss drugs giant, reached$118m in2009.
瑞士制药公司巨头诺华制药的一个非专利药品分支公司---这家名为山德士制药公司的生物仿制药品销售额在2009年达到了1亿1千8百万美元。 ecocn
Samsung Group may also set up another joint venture to make biosimilars this year, Kim said.
金泰韩说，三星集团今年还会再成立一家合资公司生产生物仿制药。 blog.sina.com.cn
That is because there is an obstacle to biosimilars even more formidable than cost: lawsuits.
这是因为在生物仿制领域有一个比成本更难以克服的障碍：法律诉讼。 ecocn
This will create more and different partnering opportunities as both Big Pharma and established biosimilars players create pipelines of compounds.
这会给大型制药公司和现有生物仿制药公司创造更多不同方式的合作机会。 dxy
This is part of a new strategy to become a “ one-stop shop” for biosimilars, explains David Simmons of Pfizer.
来自辉瑞制药的戴维西蒙斯说这是组成生物仿制制药“一站式商店”这个新战略的一部分。 ecocn
Biosimilars are a hot new area.
仿生物药品是新型热门领域。 ecocn
Biosimilars are generic impersonations although not identical copies of biotech drugs.
生物仿制制药是对生物技术制药进行的非专利仿制尽管不是完全一致的复制。 ecocn |